STAT+: ASCO showcased the payoff for new cancer medicines: longer lives
CHICAGO — Well, that’s a wrap. The biggest meeting in cancer research — and, really,…
Category: drug development
STAT+: The woman behind AstraZeneca’s cancer winning streak
CHICAGO — It was the kind of moment scientists who develop new medicines wait their…
STAT+: FDA oncology head wants advisory panels to keep voting on new drugs
CHICAGO — As commissioner of the Food and Drug Administration, Robert Califf has made clear…
STAT+: Keytruda’s benefits, a breast cancer win, the ‘dom-zim doublet’: Weekend wrap-up from ASCO
CHICAGO — The annual meeting of the American Society of Clinical Oncology is back in…
STAT+: Biotechs face challenges as the industry’s annual bash returns to Boston
The world has changed since 2018 when the Biotechnology Innovation Organization last brought its annual…
STAT+: ‘Extraordinary’ survival data for lung cancer patients is seen as boost for AstraZeneca drug
CHICAGO – Giving the AstraZeneca drug Tagrisso to patients with non-small cell lung cancer who…
.jpg)
STAT+: Pharmalittle: Pfizer touts study data for hemophilia drug; former Novartis execs cleared of bribery in Greece
Good morning, everyone, and how are you today? We are doing find, thank you, especially…
Novo says oral version of Ozempic leads to 15% weight loss
An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic…
STAT+: NIH grant recipients often fail to disclose agency support in patent applications
The National Institutes of Health may be the largest public funder of biomedical research in…
12,000 diseases lack treatments. One doctor thinks generics could yield cures
SAN FRANCISCO — About a decade ago, David Fajgenbaum thought his life was over. He…
STAT+: Sam Waksal and Jeremy Levin plot ‘the turnaround story of the century’
Over glasses of Chablis at Fleming by Le Bilboquet in Manhattan, two longtime friends and…
STAT+: Maryland pushes first-of-its-kind bill to promote alternatives to animals in biomedical research
Amid a push to use fewer animals in medical research, Maryland is on the verge…
STAT+: Stock drama, cancer vaccine success, and new science – highlights from AACR
ORLANDO, Fla. – There was some drama at the American Association for Cancer Research annual…
STAT+: Relay’s breast cancer drug proves tolerable, but market is unimpressed
ORLANDO, Fla. — Researchers presented early phase trial results on RLY-2608, Relay Therapeutics’ next-generation PI3K…
STAT+: Moderna’s mRNA cancer vaccine shows promise in combination with melanoma drug
ORLANDO, Fla. — For years, early experimental results offered hope that scientists might be able…
Merck to acquire Prometheus Biosciences, maker of autoimmune drugs, for $10.8 billion
Merck said Sunday that it will acquire Prometheus Biosciences for $10.8 billion, adding a pipeline…
STAT+: A young boy’s nightmare diagnosis, and the $3 million one-time treatment that will likely save his life
When the long-awaited moment arrived, a nurse helped Adam Hess loosen a tiny plastic clamp…
STAT+: NIH releases data showing more clinical trial sponsors are reporting results, but most miss deadlines
In response to mounting criticism, the National Institutes of Health published data that shows an…
STAT+: New research may give geneticists a long-sought tool: a targeted protein delivery device
Mark Hurst just wanted to kill some bugs. A newly credentialed bacteriologist working for the…
STAT+: Shortage of monkeys for early-stage research jeopardizes timelines for developing some drugs
A growing shortage of monkeys used for early-stage pharmaceutical research is causing concern that many…
STAT+: Top FDA official: Agency needs to start using accelerated approval for gene therapies
DALLAS — A top Food and Drug Administration official said Monday that the agency needs…
STAT+: They were the 10% left out of life-changing treatments. Now these cystic fibrosis patients may finally get help
Vertex Pharmaceuticals revolutionized the treatment of cystic fibrosis. It also has unfinished business. The Boston…
Venture capital is investing little in new treatment for addiction, report finds
There are about as many Americans living with addiction as there are Americans living with…
STAT+: ‘A cascade of failures’: FDA cites Indian drugmaker for numerous quality control problems
In a stunning rebuke, the U.S. Food and Drug Administration accused a drugmaker of a…
STAT+: Verily leans into Onduo as it looks to enter the lucrative world of running medical research
The new, streamlined Verily will have one very recognizable component: its virtual care company Onduo,…
Opinion: Stop blaming Biogen for putting profit at the expense of patients. Blame the systems that enabled it
Two congressional committees recently released damning results of an 18-month investigation into the Food and…
Opinion: Democratizing drug development will be a win for all
In 1992, the film Lorenzo’s Oil celebrated the true story of two parents who, despite…
Opinion: Is the golden age of biotech stocks over?
Much of the last decade felt like the golden age of biotechnology investing. Money —…
STAT+: Novavax replaces CEO, citing need for “fresh perspective”
The vaccine maker Novavax, which has faced several years of dramatic ups and downs around…
STAT+: Arrowhead RNA treatment improves liver scarring in patients, but so does a placebo, clouding study results
An experimental RNA treatment reduced liver scarring in half of patients with an inherited disease…
Opinion: STAT+: Continuous manufacturing can help pharma companies save time, money, and more
The pharmaceutical industry has been slow to adopt a business practice that is faster, safer,…
STAT+: Geron, biotech that once sparked talk of immortality, finally gets a (more modest) success
Geron Corporation, a biotech that made sci-fi-sounding headlines through the 90s and 2000s before shuffling…
Opinion: The Aduhelm Operetta: ‘I’ve got a little list’
The Congressional report on the FDA’s approval of Aduhelm makes some good points. As regulatory…
A letter from the executive editor: The Aduhelm Files
Dear Reader, From STAT’s first investigations in June 2021 revealing why the FDA gave the…
Opinion: Lessons learned from the deadly combination of sepsis and Covid-19
Sepsis, a deadly overreaction of the immune system to infection, has befuddled clinicians and researchers…
STAT+: Drugmakers ask regulators to change standards on new Covid antibody drugs for most vulnerable
Biotech executives and a handful of academics pleaded with U.S. and European regulators on Thursday…
STAT+: In bid to beat Bristol Myers, Takeda buys Nimbus’ anti-inflammatory drug drug for $4 billion
Takeda Pharmaceuticals said Tuesday it will spend $4 billion and offer another $2 billion in…
STAT+: Ongoing problems with a new European clinical trial registry could cause ‘catastrophe’
A coalition of pharmaceutical industry and academic medical research associations based in Germany is calling…
STAT+: Cambodia halts exports of non-human primates, threatening drug discovery efforts
Following the recent indictments of several people allegedly involved in a monkey-smuggling operation, Cambodia has…
STAT+: Medicare chief: ‘Door is really open’ on coverage for new Alzheimer’s drug
Medicare is willing to re-evaluate its coverage of Alzheimer’s drugs in light of a new…
STAT+: “This is not a cure”: Consensus begins to emerge on new Alzheimer’s drug
NEW YORK — A consensus may be emerging about how to prescribe the new Alzheimer’s…
.jpg)
Opinion: Breakthrough Therapies Act: Good idea, wrong solution
The Breakthrough Therapies Act, recently proposed by Senators Rand Paul (R-Ky.) and Cory Booker (D-N.J.)…
STAT+: On the long road to treating Huntington’s genetic stutter, scientists return to overlooked clues
In the spring of 1981, a geneticist from Indianapolis and a neurologist from Chicago got…
STAT+: Vertex revolutionized cystic fibrosis treatment. Its executives say that’s just the start
BOSTON — Vertex Pharmaceuticals reshaped the way doctors treat cystic fibrosis, turning what was once…
STAT+: ‘We were right all along:’ For Japanese drugmaker Eisai, success against Alzheimer’s has been a long time coming
NUTLEY, N.J. — A once-in-a-generation medicine was built on more than two decades of regret….
After decades of setbacks, scientists make strides toward the holy grail of male birth control
The headlines spelled the end of a short-lived scientific hope: “Male birth control study nixed…
STAT+: More drugmakers are expanding access in poorer countries, but progress continues to lag overall
For the first time, many of the world’s largest pharmaceutical companies are taking concrete steps…
STAT+: After blazing trails in RNA-targeted drugs, Ionis jumps into gene editing
Ionis Pharmaceuticals, the California company that turned RNA-targeting medicines from an unproven idea into blockbuster…
U.S. set to face third Covid winter without key tools and treatments
The country is heading into its third Covid winter without crucial tools we’ve relied on…
STAT+: FDA panel votes against Veru’s drug for severe Covid
An FDA advisory panel voted 5-to-8 to recommend rejecting a new drug for patients hospitalized…